Video
Elizabeth A. Thiele, MD, PhD
Dr. Thiele describes a study of cannabidiol in children with Lennox-Gastaut syndrome.
Video
Justin Gover
Justin Gover, Chief Executive Officer of Greenwich Biosciences, discusses the FDA's planned review of Epidiolex, a formulation of cannabidiol, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.
Recommended Reading
Related Articles
-
-
Conference Coverage
Cannabidiol Reduces Drop Seizures in Patients With Lennox-Gastaut Syndrome
BOSTON―Cannabidiol (CBD) as an add-on therapy may reduce drop seizures by 50% in some adults and children with Lennox-Gastaut...
Conference Coverage
-
Noninvasive testing in midlife flags late-onset epilepsy risk -
Novel neural cell therapy: A cure for focal epilepsy? -
Seizures in dementia hasten decline and death -
-
‘Striking’ rate of mental health comorbidities in epilepsy -
Significant racial disparities persist in status epilepticus -
-
-
Diazepam nasal spray effective in Lennox-Gastaut syndrome -
Literature Review
-
-
Modified Atkins diet beneficial in drug-resistant epilepsy -
-
Strong two-way link between epilepsy and depression -
High drug costs exclude most neurology patients from cutting-edge treatment -
Drug-resistant epilepsy needs earlier surgical referral -
‘Striking’ jump in cost of brand-name epilepsy meds -
Air pollution is a seizure trigger for patients with epilepsy -
New guidance on cannabis use for treatment-resistant epilepsy -
Question 1 of 5